These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10579828)

  • 1. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
    Bartolomé-Nebreda JM; Gómez-Monterrey I; García-López MT; González-Muñiz R; Martín-Martínez M; Ballaz S; Cenarruzabeitia E; LaTorre M; Del Río J; Herranz R
    J Med Chem; 1999 Nov; 42(22):4659-68. PubMed ID: 10579828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
    Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
    J Med Chem; 2001 Nov; 44(24):4196-206. PubMed ID: 11708921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
    J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
    Bartolomé-Nebreda JM; Patiño-Molina R; Martín-Martínez M; Gómez-Monterrey I; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
    J Med Chem; 2001 Jun; 44(13):2219-28. PubMed ID: 11405658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
    Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
    J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
    Latorre M; Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Herranz R; Del Río J; Cenarruzabeitia E
    Pharmacology; 2004 Oct; 72(2):68-76. PubMed ID: 15331911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CCK-B antagonists.
    Horwell DC
    Neuropeptides; 1991 Jul; 19 Suppl():57-64. PubMed ID: 1881533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Turned dipeptoids as potent and selective CCK(1) receptor antagonists.
    Martín-Martínez M; De La Figuera N; Latorre M; Herranz R; García-López MT; Cenarruzabeitia E; Del Río J; González-Muñiz R
    J Med Chem; 2000 Oct; 43(20):3770-7. PubMed ID: 11020292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion.
    Saluja AK; Saluja M; Printz H; Zavertnik A; Sengupta A; Steer ML
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8968-71. PubMed ID: 2479032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
    Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
    Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
    Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.
    Shiosaki K; Lin CW; Kopecka H; Craig RA; Bianchi BR; Miller TR; Witte DG; Stashko M; Nadzan AM
    J Med Chem; 1992 May; 35(11):2007-14. PubMed ID: 1375964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.
    Holladay MW; Bennett MJ; Tufano MD; Lin CW; Asin KE; Witte DG; Miller TR; Bianchi BR; Nikkel AL; Bednarz L
    J Med Chem; 1992 Aug; 35(16):2919-28. PubMed ID: 1501220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
    Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
    J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.